Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Inv. presentation
Appointed director
Diadexus, Inc. (DDXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/28/2016 8-K Quarterly results
04/18/2016 8-K Form 8-K - Current report
04/01/2016 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
03/28/2016 8-K Quarterly results
Docs: "Press Release entitled “Updated - Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results.”"
03/17/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/26/2015 8-K Quarterly results
Docs: "PLAC ® ELISA o Signed an exclusive, license and supply agreement granting OriGene rights to develop and commercialize Diadexus' proprietary PLAC ® ELISA in certain Asian countries . Diadexus will supply to OriGene the raw materials and reagents necessary to assemble, develop, produce, seek marketing authorization for, and sell PLAC ® ELISA in the Territory. Upon commencement of commercial sales, Diadexus is eligible to receive sales-based milestones as well as mid-single-digit royalties on net sales. 3 ● PLAC ® Activity o A new partnership established with Mayo Clinic for the integration and use of PLAC ® Activity testing into clinical practice. The parties recently completed a successful kick-off meeting with key sales and marketing personnel. Once fully integrated, the test will be..."
09/08/2015 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
08/20/2015 8-K Regulation FD Disclosure
08/13/2015 8-K Quarterly results
Docs: "Diadexus, Inc. Reports Second Quarter 2015 Financial Results",
"Diadexus, Inc. Reports Second Quarter 2015 Financial Results"
07/02/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/01/2015 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Diadexus, Inc"
06/10/2015 8-K Submission of Matters to a Vote of Security Holders
05/12/2015 8-K Quarterly results
Docs: "Diadexus, Inc. Reports First Quarter 2015 Financial Results"
04/17/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement, by and among diaDexus, Inc., Leap Tide Capital Management, LLC and Jan Loeb"
03/12/2015 8-K Quarterly results
Docs: "Diadexus, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results"
03/09/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "diaDexus, Inc. Announces Appointment of Leone Patterson as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., March 2, 2015 — diaDexus, Inc. , a company developing and commercializing proprietary cardiovascular diagnostic products, today announced the appointment of Leone Patterson as chief financial officer. “We are fortunate to have Leone join our new leadership team as we work together to create value through evolving diaDexus into a multi-product company with significant growth potential,” said Lori Rafield, Ph.D., chairman of the board of directors and interim chief executive officer of diaDexus. “Leone has extensive financial, accounting, and business experience, gained in roles of increasing responsibility at Net App, Exelixis, Novartis, Chiron, and KPMG. Most recently, she was th..."
03/02/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "diaDexus, Inc. Announces Appointment of John Curnutte, M.D., Ph.D. to its Board of Directors SOUTH SAN FRANCISCO, Calif., February 24, 2015 — diaDexus, Inc. , a company developing and commercializing proprietary cardiovascular diagnostic products, today announced the appointment of John Curnutte, M.D., Ph.D. as an independent member of its board of directors effective immediately. Dr. Curnutte will serve on the compensation committee. The Company also announced that Adeoye Olukotun, M.D. does not plan to stand for reelection at the 2015 Annual Meeting of Stockholders. “John brings extensive clinical development expertise to diaDexus, and we are delighted to have him join our Board of Directors,” said Lori Rafield, Ph.D., chairman of the board and interim chief executive officer for diaDexu..."
02/11/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/07/2015 8-K Resignation/termination of a director
Docs: "diaDexus, Inc. Announces Appointment of James Sulat and Elizabeth Hutt to its Board of Directors SOUTH SAN FRANCISCO, Calif. — — diaDexus, Inc. , a company developing and commercializing proprietary cardiovascular diagnostic products, today announced the appointment of James Sulat and Elizabeth Hutt as members of its board of directors effective immediately. Mr. Sulat will serve as chairman of the audit committee and will serve on the nominating and corporate governance committee. Ms. Hutt will serve on the audit and compensation committees. The Company also announced the resignations of Andrew Galligan, James Panek, and Charles Patrick from its Board of Directors. “We are honored to have Jim and Elizabeth join the board of directors at this important juncture as diaDexus evolves into a mu..."
01/05/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "diaDexus, Inc. Updates on 2014 Achievements and 2015 Initiatives"
12/29/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/18/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "diaDexus, Inc. Amended and Restated Key Employee Severance Benefit Plan, adopted December 15, 2014"
11/05/2014 8-K Quarterly results
Docs: "--"
09/22/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "diaDexus, Inc. Announces Appointment of Kenneth Fang, M.D., as Chief Medical Officer --Company Also Discloses Departure of Michael Richey as Chief Business Officer--"
09/11/2014 8-K Entry into a Material Definitive Agreement
09/11/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "diaDexus, Inc. Announces Resignation of Chief Financial Officer"
08/21/2014 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Loan and Security Agreement, by and between diaDexus, Inc. and Oxford Finance LLC",
"diaDexus, Inc. Secures $15 Million Debt Financing"
07/28/2014 8-K Quarterly results
Docs: "diaDexus, Inc. Reports Second Quarter 2014 Financial Results 23 Percent Year-Over-Year Revenue Growth Conference Call Today at 4:30 p.m. ET"
07/18/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "diaDexus Announces FDA Acceptance for Review of 510 Submission for PLAC Test for Lp-PLA 2 Activity SOUTH SAN FRANCISCO, Calif., July 17, 2014 — diaDexus, Inc. , a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it has received notice from the U.S. Food and Drug Administration that an administrative acceptance review was conducted on the traditional 510 submission of the PLAC Test for Lp-PLA 2 Activity, and it was found to contain all of the necessary information needed to proceed with the substantive review. The PLAC Test for Lp-PLA 2 Activity is an enzyme assay for the quantitative determination of Lp-PLA 2 activity in human plasma and serum. “We have been working closely with the FDA through the pre-submission process to determi..."
06/26/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "DIADEXUS ANNOUNCES LEADERSHIP CHANGES TO DRIVE AND SUPPORT FUTURE GROWTH POTENTIAL"
06/02/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "diaDexus, Inc. 2012 Equity Incentive Award Plan, as amended on May 29, 2014"
05/07/2014 8-K Quarterly results
Docs: "diaDexus, Inc. Reports First Quarter 2014 Financial Results"
05/01/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "diaDexus Announces Completion of Validation Cohort for the PLAC ® Test for Lp-PLA 2 Activity"
04/29/2014 8-K Entry into a Material Definitive Agreement
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy